1. Home
  2. WINT vs PRSO Comparison

WINT vs PRSO Comparison

Compare WINT & PRSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WINT
  • PRSO
  • Stock Information
  • Founded
  • WINT 1992
  • PRSO 2008
  • Country
  • WINT United States
  • PRSO United States
  • Employees
  • WINT N/A
  • PRSO N/A
  • Industry
  • WINT Biotechnology: Biological Products (No Diagnostic Substances)
  • PRSO Semiconductors
  • Sector
  • WINT Health Care
  • PRSO Technology
  • Exchange
  • WINT Nasdaq
  • PRSO Nasdaq
  • Market Cap
  • WINT 3.6M
  • PRSO 4.3M
  • IPO Year
  • WINT 1995
  • PRSO 2001
  • Fundamental
  • Price
  • WINT $0.57
  • PRSO $1.20
  • Analyst Decision
  • WINT Hold
  • PRSO Strong Buy
  • Analyst Count
  • WINT 1
  • PRSO 2
  • Target Price
  • WINT $350.00
  • PRSO $3.38
  • AVG Volume (30 Days)
  • WINT 264.4K
  • PRSO 221.2K
  • Earning Date
  • WINT 05-16-2025
  • PRSO 05-12-2025
  • Dividend Yield
  • WINT N/A
  • PRSO N/A
  • EPS Growth
  • WINT N/A
  • PRSO N/A
  • EPS
  • WINT N/A
  • PRSO N/A
  • Revenue
  • WINT N/A
  • PRSO $15,626,000.00
  • Revenue This Year
  • WINT N/A
  • PRSO $3.96
  • Revenue Next Year
  • WINT N/A
  • PRSO $36.80
  • P/E Ratio
  • WINT N/A
  • PRSO N/A
  • Revenue Growth
  • WINT N/A
  • PRSO 35.50
  • 52 Week Low
  • WINT $0.55
  • PRSO $0.52
  • 52 Week High
  • WINT $737.44
  • PRSO $2.34
  • Technical
  • Relative Strength Index (RSI)
  • WINT 26.04
  • PRSO 68.85
  • Support Level
  • WINT $0.67
  • PRSO $0.86
  • Resistance Level
  • WINT $0.81
  • PRSO $1.00
  • Average True Range (ATR)
  • WINT 0.06
  • PRSO 0.09
  • MACD
  • WINT 0.01
  • PRSO 0.02
  • Stochastic Oscillator
  • WINT 5.24
  • PRSO 100.00

About WINT Windtree Therapeutics Inc.

Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.

About PRSO Peraso Inc.

Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz, to 300 GHz. Geographically the company generates revenue from the United States, Hong Kong, Taiwan, and the Rest of the World.

Share on Social Networks: